Homology modeling, molecular dynamics and QM/MM study of the regulatory protein PhoP from Corynebacterium

Gleiciane Moraes1, Vasco Azevedo, Marcília Costa

  • 1Laboratório de Planejamento e Desenvolvimento de Fármacos, Universidade Federal do Pará, Belém, PA, Brazil.

Insights

We modeled the 3D structure of Corynebacterium pseudotuberculosis PhoP protein, revealing key magnesium ion interactions. This structural insight could guide new vaccine development against caseous lymphadenitis.

Area of Science:

  • Bacteriology
  • Structural Biology
  • Vaccine Development

Background:

  • Corynebacterium pseudotuberculosis causes significant economic losses in livestock through caseous lymphadenitis.
  • The PhoPR two-component system (TCS) regulates virulence in this pathogen.
  • PhoP protein phosphorylation, essential for TCS activation, requires magnesium ions.

Purpose of the Study:

  • To determine the 3D structure of the Corynebacterium pseudotuberculosis PhoP protein.
  • To investigate the interaction between the PhoP protein and magnesium ions.
  • To provide structural insights for potential vaccine development.

Main Methods:

  • Homology modeling was used to generate the 3D structure of the full-length PhoP protein.
  • Molecular dynamics simulations assessed the stability of the generated PhoP model.
  • Quantum mechanical/molecular mechanical (QM/MM) techniques were employed to optimize energy and determine protein-Mg(2+) interactions.

Main Results:

  • The study presents the first 3D structural model of a full-length OmpR/PhoP subfamily member.
  • Analysis identified Asp-16 and Asp-59 as critical residues for magnesium ion binding to PhoP.
  • The interaction energy analysis revealed specific binding sites for Mg(2+).

Conclusions:

  • The structural and energetic data of PhoP-Mg(2+) interactions offer a foundation for rational drug design.
  • Targeting PhoP through mutations, particularly at Asp-16 and Asp-59, could lead to novel vaccine strategies.
  • This research paves the way for developing genetic attenuation-based vaccines against C. pseudotuberculosis infections.